Storgate LLC Invests $685,000 in Teva Pharmaceutical Industries Ltd. $TEVA

Storgate LLC bought a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 4th quarter, HoldingsChannel reports. The fund bought 21,948 shares of the company’s stock, valued at approximately $685,000.

Other hedge funds also recently made changes to their positions in the company. Allworth Financial LP grew its position in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust grew its position in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Teva Pharmaceutical Industries by 567.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after acquiring an additional 1,134 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 21,258 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares of the company’s stock, valued at $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TEVA shares. Truist Financial lifted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Stock Up 0.0%

NYSE:TEVA opened at $34.58 on Friday. The firm has a market capitalization of $39.75 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 3.53 and a beta of 0.84. The stock has a 50 day moving average of $33.28 and a 200-day moving average of $31.96. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.